Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

23/07/24	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.	CI
09/12/21	TearLab Corporation Announces Board Appointments	CI
09/12/21	TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer	CI
09/11/21	Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors	CI
16/09/21	MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans	CI
29/07/20	TearLab Appoints Adam Szaronos as Chief Commercial Officer	CI
09/07/20	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.	CI
09/07/20	TearLab Corporation to Seek Acquisitions	CI
27/06/20	Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
11/05/20	TearLab Corporation Announces Board Appointments	CI
11/05/20	Tearlab Mulls Inorganic Growth Opportunities	CI
11/05/20	TearLab Corporation announced that it expects to receive $25 million in funding from Accelmed Fund	CI
11/05/20	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) entered into term sheet to acquire TearLab Corporation for $0.74 million.	CI

09/07/20	TEARLAB CORP : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
27/06/20	TearLab: 1Q Earnings Snapshot	AQ
27/06/20	TEARLAB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
09/06/20	TEARLAB : Entry into a Material Definitive Agreement (form 8-K/A)	AQ
30/05/20	TEARLAB CORP : Entry into a Material Definitive Agreement (form 8-K)	AQ

Manager	Title	Age	Since
Adam Szaronos CEO	Chief Executive Officer	-	01/04/2026
Benjamin Sullivan CTO	Chief Tech/Sci/R&D Officer	-	17/07/2009
John Lund DFI	Director of Finance/CFO	60	01/07/2022

Director	Title	Age	Since
Uri Geiger BRD	Director/Board Member	58	09/07/2020
James V. Mazzo CHM	Chairman	68	09/12/2021
Richard Lindstrom BRD	Director/Board Member	78	01/09/2004

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
9/7/20	Joseph S. Jensen	Tender	Chief Executive Officer	29,206	0.1196%
9/7/20	Michael Marquez	Tender	Chief Financial Officer	500	0.0020%	-
9/7/20	Paul M. Karpecki	Tender	Director	102,200	0.4187%

TearLab Corporation Stock

Stocks

Medical Equipment, Supplies & Distribution

Latest news: TearLab Corporation

Press Releases: TearLab Corporation

Managers and Directors: TearLab Corporation

Latest insider transactions

Glasses, Spectacles & Contact Lenses

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TEARLAB CORPORATION	-.--%	+2.84%	-	-	1.41M
ESSILORLUXOTTICA	+0.89%	-1.40%	-44.20%	-15.08%	78.09B
ALCON INC.	+1.89%	-4.01%	-12.22%	-24.35%	31.98B
LENSKART SOLUTIONS LIMITED	-1.67%	-0.46%	-	-	12.41B
THE COOPER COMPANIES, INC.	+0.58%	-22.09%	-18.69%	-37.07%	10.25B
SHANGHAI CONANT OPTICAL CO., LTD.	-3.15%	-2.14%	-4.67%	+545.77%	2.63B
AUTEK CHINA INC.	+0.70%	-9.24%	-44.43%	-61.39%	1.33B
SPYGLASS PHARMA, INC.	+4.14%	-0.97%	-	-	920M
PEGAVISION CORPORATION	+3.81%	-0.91%	+23.06%	+9.16%	892M
MINGYUE OPTICAL LENS CO.,LTD.	+1.14%	-5.34%	-39.43%	-25.01%	839M
Average	+0.83%	-5.15%	-20.08%	+56.00%	15.48B
Weighted average by Cap.	+0.83%	-4.41%	-32.68%	-7.91%